{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T06:02:07Z","timestamp":1784872927075,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T00:00:00Z","timestamp":1784419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Rare breast cancers represent a clinically important but underrepresented group of malignancies. In this Perspective, rare breast cancers are considered within the broader rare cancer definition of an annual incidence below 6 cases per 100,000 persons, while also recognizing breast-specific rarity based on uncommon histology, molecular hallmarks, clinical presentation or sex-specific occurrence. These conditions are characterized by limited case numbers, biological heterogeneity, reduced clinical trial inclusion and fragmented evidence. These constraints challenge artificial intelligence (AI) development because many systems depend on large, balanced and externally validated datasets. AI may support diagnosis, histopathology, molecular interpretation, prognostic stratification and precision oncology decision support, but its use in rare breast cancers requires evidence standards adapted to small cohorts. This Perspective proposes an evidence-informed clinical governance framework organized around five domains: intended clinical use, small-cohort validation, synthetic data governance, human oversight and lifecycle monitoring. Its distinctive contribution is to translate general AI reporting and governance principles into rare breast cancer-specific safeguards, including objective data-quality checks, leakage prevention, uncertainty-aware validation, synthetic data plausibility scoring, pan-rare model reporting, patient involvement and post-deployment surveillance. Synthetic data may support development and simulation, but should not replace validation on real clinical cases. By linking small-cohort methodology with clinical oversight, regulatory alignment and lifecycle monitoring, the framework offers a practical roadmap for safe AI-enabled rare breast cancer precision oncology.<\/jats:p>","DOI":"10.1007\/s12672-026-05573-1","type":"journal-article","created":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T04:44:16Z","timestamp":1784436256000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["An evidence informed framework for artificial intelligence in rare breast cancers using small cohort validation synthetic data practices and clinical governance"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9284-4262","authenticated-orcid":false,"given":"Bandar Saad","family":"Alshreef","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,19]]},"reference":[{"key":"5573_CR1","unstructured":"NPJ Precision Oncology. Demystifying Rare Breast Cancers. Nature Portfolio. https:\/\/www.nature.com\/collections\/ahghebfcda. Accessed 29 Apr 2026."},{"key":"5573_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41523-025-00719-w","volume":"11","author":"F Pareja","year":"2025","unstructured":"Pareja F, Bhargava R, Borges VF, Brogi E, Canas Marques R, Cardoso F, et al. Unraveling complexity and leveraging opportunities in uncommon breast cancer subtypes. NPJ Breast Cancer. 2025;11:6. https:\/\/doi.org\/10.1038\/s41523-025-00719-w.","journal-title":"NPJ Breast Cancer"},{"issue":"5","key":"5573_CR3","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s11912-021-01048-4","volume":"23","author":"S Jenkins","year":"2021","unstructured":"Jenkins S, Kachur ME, Rechache K, et al. Rare breast cancer subtypes. Curr Oncol Rep. 2021;23(5):54. https:\/\/doi.org\/10.1007\/s11912-021-01048-4.","journal-title":"Curr Oncol Rep"},{"key":"5573_CR4","unstructured":"World Health Organization. Breast cancer. Fact sheet. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/breast-cancer Accessed 16 Apr 2026."},{"key":"5573_CR5","unstructured":"Centers for Disease Control and Prevention. About breast cancer in men. https:\/\/www.cdc.gov\/breast-cancer\/about\/men.html Accessed 16 Sep 2024."},{"issue":"7788","key":"5573_CR6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41586-019-1799-6","volume":"577","author":"SM McKinney","year":"2020","unstructured":"McKinney SM, Sieniek M, Godbole V, Godwin J, Antropova N, Ashrafian H, et al. International evaluation of an AI system for breast cancer screening. Nature. 2020;577(7788):89\u201394. https:\/\/doi.org\/10.1038\/s41586-019-1799-6.","journal-title":"Nature"},{"key":"5573_CR7","doi-asserted-by":"crossref","unstructured":"Chua BN et al. Artificial intelligence for breast cancer management. 2026. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12873274\/","DOI":"10.1038\/s43856-025-01342-3"},{"key":"5573_CR8","unstructured":"Hsu CY et al. AI-driven multi-omics integration in precision oncology. 2025. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12634751\/"},{"key":"5573_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41523-025-00857-1","volume":"11","author":"C Frascarelli","year":"2025","unstructured":"Frascarelli C, Venetis K, Marra A, Concardi A, D\u2019Ercole M, Mangione E, et al. Computational pathology in breast cancer: optimizing molecular prediction through task-oriented AI models. NPJ Breast Cancer. 2025;11:141. https:\/\/doi.org\/10.1038\/s41523-025-00857-1.","journal-title":"NPJ Breast Cancer"},{"key":"5573_CR10","unstructured":"Ding T et al. A multimodal whole-slide foundation model for pathology. Nat Med. 2025. https:\/\/www.nature.com\/articles\/s41591-025-03982-3"},{"key":"5573_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03141-0","author":"E Vorontsov","year":"2024","unstructured":"Vorontsov E, et al. A foundation model for clinical-grade computational pathology and rare cancers detection. Nat Med. 2024. https:\/\/doi.org\/10.1038\/s41591-024-03141-0.","journal-title":"Nat Med"},{"key":"5573_CR12","doi-asserted-by":"publisher","first-page":"e078378","DOI":"10.1136\/bmj-2023-078378","volume":"385","author":"GS Collins","year":"2024","unstructured":"Collins GS, Dhiman P, Andaur Navarro CL, Ma J, Hooft L, Reitsma JB, et al. TRIPOD\u2009+\u2009AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ. 2024;385:e078378. https:\/\/doi.org\/10.1136\/bmj-2023-078378.","journal-title":"BMJ"},{"issue":"4","key":"5573_CR13","doi-asserted-by":"publisher","first-page":"e240300","DOI":"10.1148\/ryai.240300","volume":"6","author":"AS Tejani","year":"2024","unstructured":"Tejani AS, Klontzas ME, Gatti AA, Mongan JT, Moy L, Park SH, Kahn CE Jr. CLAIM 2024 Update Panel. Checklist for Artificial Intelligence in Medical Imaging: 2024 Update. Radiol Artif Intell. 2024;6(4):e240300. https:\/\/doi.org\/10.1148\/ryai.240300.","journal-title":"Radiol Artif Intell"},{"issue":"23","key":"5573_CR14","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.3390\/diagnostics15232996","volume":"15","author":"F Pesapane","year":"2025","unstructured":"Pesapane F, D\u2019Amelio L, Nicosia L, Mallardi C, Bozzini A, Meneghetti L, Carrafiello G, Cassano E, Santicchia S. The role of synthetic data and generative AI in breast imaging: promise, pitfalls, and pathways forward. Diagnostics. 2025;15(23):2996. https:\/\/doi.org\/10.3390\/diagnostics15232996.","journal-title":"Diagnostics"},{"key":"5573_CR15","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41746-024-01359-3","volume":"8","author":"B Kaabachi","year":"2025","unstructured":"Kaabachi B, Despraz J, Meurers T, Otte K, Halilovic M, Kulynych B, Prasser F, et al. A scoping review of privacy and utility metrics in medical synthetic data. NPJ Digit Med. 2025;8:60.","journal-title":"NPJ Digit Med"},{"key":"5573_CR16","doi-asserted-by":"publisher","first-page":"e081554","DOI":"10.1136\/bmj-2024-081554","volume":"388","author":"K Lekadir","year":"2025","unstructured":"Lekadir K, et al. FUTURE-AI: international consensus guideline for trustworthy and deployable artificial intelligence in healthcare. BMJ. 2025;388:e081554. https:\/\/doi.org\/10.1136\/bmj-2024-081554.","journal-title":"BMJ"},{"key":"5573_CR17","unstructured":"US Food and Drug Administration. Artificial intelligence in software as a medical device. https:\/\/www.fda.gov\/medical-devices\/software-medical-device-samd\/artificial-intelligence-software-medical-device Accessed 25 Mar 2025."},{"key":"5573_CR18","unstructured":"US Food and Drug Administration. Good Machine Learning Practice for Medical Device Development. Guiding Principles. https:\/\/www.fda.gov\/medical-devices\/software-medical-device-samd\/good-machine-learning-practice-medical-device-development-guiding-principles Accessed 19 Dec 2025."},{"key":"5573_CR19","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1038\/s41591-020-1034-x","volume":"26","author":"X Liu","year":"2020","unstructured":"Liu X, Rivera SC, Moher D, Calvert MJ, Denniston AK, SPIRIT-AI, CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension. Nat Med. 2020;26:1364\u201374.","journal-title":"Nat Med"},{"key":"5573_CR20","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/s41591-020-1037-7","volume":"26","author":"SC Rivera","year":"2020","unstructured":"Rivera SC, Liu X, Chan AW, Denniston AK, Calvert MJ, SPIRIT-AI, CONSORT-AI Working Group. Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI extension. Nat Med. 2020;26:1351\u201363.","journal-title":"Nat Med"},{"key":"5573_CR21","doi-asserted-by":"crossref","unstructured":"Alderman JE et al. Tackling algorithmic bias and promoting transparency in health datasets for artificial intelligence: the STANDING Together recommendations. Lancet Digit Health. 2025.","DOI":"10.1016\/S2589-7500(24)00224-3"},{"key":"5573_CR22","volume-title":"Ethics and governance of artificial intelligence for health: WHO guidance","author":"World Health Organization","year":"2021","unstructured":"World Health Organization. Ethics and governance of artificial intelligence for health: WHO guidance. Geneva: World Health Organization; 2021."},{"key":"5573_CR23","first-page":"1","volume":"L117","author":"European Parliament and Council","year":"2017","unstructured":"European Parliament and Council. Regulation (EU) 2017\/745 of 5 April 2017 on medical devices. Official J Eur Union. 2017;L117:1\u2013175.","journal-title":"Official J Eur Union"},{"key":"5573_CR24","first-page":"176","volume":"L117","author":"European Parliament and Council","year":"2017","unstructured":"European Parliament and Council. Regulation (EU) 2017\/746 of 5 April 2017 on in vitro diagnostic medical devices. Official J Eur Union. 2017;L117:176\u2013332.","journal-title":"Official J Eur Union"},{"issue":"5","key":"5573_CR25","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s42256-019-0048-x","volume":"1","author":"C Rudin","year":"2019","unstructured":"Rudin C. Stop explaining black box machine learning models for high stakes decisions and use interpretable models instead. Nat Mach Intell. 2019;1(5):206\u201315. https:\/\/doi.org\/10.1038\/s42256-019-0048-x.","journal-title":"Nat Mach Intell"},{"key":"5573_CR26","unstructured":"European Society for Medical Oncology. Definition of rare cancers, ESMO Rare Cancers Working Group. Available from: https:\/\/www.esmo.org\/policy\/esmo-public-policy-committee\/rare-cancers-working-group\/what-are-rare-cancers\/definition-of-rare-cancers"},{"key":"5573_CR27","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12943-026-02568-y","volume":"25","author":"Y Luo","year":"2026","unstructured":"Luo Y, Tian W, Zhu X, Wei W, Ye F, Situ MY, et al. piR-1170 drives brain metastasis and immune evasion via WTAP-mediated m6A methylation reprogramming in triple-negative breast cancer. Mol Cancer. 2026;25:52. https:\/\/doi.org\/10.1186\/s12943-026-02568-y.","journal-title":"Mol Cancer"},{"key":"5573_CR28","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12943-024-02140-6","volume":"23","author":"SB Guo","year":"2024","unstructured":"Guo SB, Meng Y, Lin L, Zhou ZZ, Li HL, Tian XP, et al. Artificial intelligence alphafold model for molecular biology and drug discovery: a machine-learning-driven informatics investigation. Mol Cancer. 2024;23:223. https:\/\/doi.org\/10.1186\/s12943-024-02140-6.","journal-title":"Mol Cancer"},{"key":"5573_CR29","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1097\/JS9.0000000000003668","volume":"112","author":"SB Guo","year":"2025","unstructured":"Guo SB, Liu DY, Fang XJ, Meng Y, Zhou ZZ, Li J, et al. Current concerns and future directions of large language model ChatGPT in medicine: a machine-learning-driven global-scale bibliometric analysis. Int J Surg. 2025;112:2805\u201322. https:\/\/doi.org\/10.1097\/JS9.0000000000003668.","journal-title":"Int J Surg"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-05573-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05573-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05573-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:13:48Z","timestamp":1784870028000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-05573-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,19]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5573"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-05573-1","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,19]]},"assertion":[{"value":"30 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval was not required because this article does not involve human participants, identifiable patient data or animal experiments.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1076"}}